Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study
Abstract Background Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder causing excessive oxalate production, damaging kidneys and other organs. Nedosiran, launched in the U.S. for individuals with PH1 (≥ 9 years of age; estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2), can...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-025-03738-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849734127955214336 |
|---|---|
| author | David S. Goldfarb Jing Voon Chen Rebekah Zincavage Brad Padilla Matthew Sussman Sandra Salem Frank Modersitzki |
| author_facet | David S. Goldfarb Jing Voon Chen Rebekah Zincavage Brad Padilla Matthew Sussman Sandra Salem Frank Modersitzki |
| author_sort | David S. Goldfarb |
| collection | DOAJ |
| description | Abstract Background Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder causing excessive oxalate production, damaging kidneys and other organs. Nedosiran, launched in the U.S. for individuals with PH1 (≥ 9 years of age; estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2), can be self- or caregiver-administered at home with fixed-dosing for patients ≥ 12 years of age. This real-world study aimed to understand treatment preferences among individuals with PH1, highlighting challenges in administration of current treatments. Methods A cross-sectional web-based survey was conducted among U.S.-based adults (aged ≥ 18) diagnosed with PH1. The survey consisted of a 20–25 min questionnaire and was conducted from October to December 2023. Results The study participants (N = 39) included both male (N = 26) and female (N = 13) adults with PH1. Participants came from a range of community settings, including urban (46%), rural (39%), and suburban (15%); and were full- or part-time workers (56%) or students (41%). Most participants were on lumasiran therapy (95%) for an average of 1 year (range: 0.3–1.8 years). The survey revealed that the commonly reported factors important for treatment selection among participants living with PH1 were frequency of administration, treatment administrator, time required for treatment, and place of administration. The ability to self-administer was ranked as the top choice by most participants. Over half (56%) found quarterly injections easy or very easy. Similarly, 56–59% found home administration, whether self- or healthcare provider (HCP)-administered, easy or very easy. Nearly half (46%) considered injections at medical facilities challenging or very challenging. The majority indicated traveling > 15 min for injections would be burdensome (57%) and arranging appointments problematic (54%). When comparing administration methods, 72% preferred self-injection over HCP-administered injections. Regarding treatment regimens, 57% found it easy or very easy to receive monthly injections initially, before switching to quarterly. Additionally, 64% preferred a medication dosage that is not weight-based. While participants expressed a preference for less frequent treatments, 67% preferred self-injection at home over medical facility injections, and 67% preferred monthly injections at home over quarterly injections at a medical facility. Conclusions This study shows that patients with PH1 value treatments that are convenient and fit their lifestyle. |
| format | Article |
| id | doaj-art-693716bd80a04e828e2cb0d79629ce20 |
| institution | DOAJ |
| issn | 1750-1172 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj-art-693716bd80a04e828e2cb0d79629ce202025-08-20T03:07:51ZengBMCOrphanet Journal of Rare Diseases1750-11722025-05-0120111110.1186/s13023-025-03738-9Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world studyDavid S. Goldfarb0Jing Voon Chen1Rebekah Zincavage2Brad Padilla3Matthew Sussman4Sandra Salem5Frank Modersitzki6Division of Nephrology, NYU Langone Health and NYU Grossman School of MedicineGenesis Research GroupStrateviStrateviStrateviNovo Nordisk IncDivision of Nephrology, NYU Langone Health and NYU Grossman School of MedicineAbstract Background Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder causing excessive oxalate production, damaging kidneys and other organs. Nedosiran, launched in the U.S. for individuals with PH1 (≥ 9 years of age; estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2), can be self- or caregiver-administered at home with fixed-dosing for patients ≥ 12 years of age. This real-world study aimed to understand treatment preferences among individuals with PH1, highlighting challenges in administration of current treatments. Methods A cross-sectional web-based survey was conducted among U.S.-based adults (aged ≥ 18) diagnosed with PH1. The survey consisted of a 20–25 min questionnaire and was conducted from October to December 2023. Results The study participants (N = 39) included both male (N = 26) and female (N = 13) adults with PH1. Participants came from a range of community settings, including urban (46%), rural (39%), and suburban (15%); and were full- or part-time workers (56%) or students (41%). Most participants were on lumasiran therapy (95%) for an average of 1 year (range: 0.3–1.8 years). The survey revealed that the commonly reported factors important for treatment selection among participants living with PH1 were frequency of administration, treatment administrator, time required for treatment, and place of administration. The ability to self-administer was ranked as the top choice by most participants. Over half (56%) found quarterly injections easy or very easy. Similarly, 56–59% found home administration, whether self- or healthcare provider (HCP)-administered, easy or very easy. Nearly half (46%) considered injections at medical facilities challenging or very challenging. The majority indicated traveling > 15 min for injections would be burdensome (57%) and arranging appointments problematic (54%). When comparing administration methods, 72% preferred self-injection over HCP-administered injections. Regarding treatment regimens, 57% found it easy or very easy to receive monthly injections initially, before switching to quarterly. Additionally, 64% preferred a medication dosage that is not weight-based. While participants expressed a preference for less frequent treatments, 67% preferred self-injection at home over medical facility injections, and 67% preferred monthly injections at home over quarterly injections at a medical facility. Conclusions This study shows that patients with PH1 value treatments that are convenient and fit their lifestyle.https://doi.org/10.1186/s13023-025-03738-9Primary hyperoxaluriaReal-world studyPatient surveyTreatment preferences |
| spellingShingle | David S. Goldfarb Jing Voon Chen Rebekah Zincavage Brad Padilla Matthew Sussman Sandra Salem Frank Modersitzki Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study Orphanet Journal of Rare Diseases Primary hyperoxaluria Real-world study Patient survey Treatment preferences |
| title | Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study |
| title_full | Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study |
| title_fullStr | Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study |
| title_full_unstemmed | Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study |
| title_short | Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study |
| title_sort | treatment preferences among individuals with primary hyperoxaluria type 1 ph1 a real world study |
| topic | Primary hyperoxaluria Real-world study Patient survey Treatment preferences |
| url | https://doi.org/10.1186/s13023-025-03738-9 |
| work_keys_str_mv | AT davidsgoldfarb treatmentpreferencesamongindividualswithprimaryhyperoxaluriatype1ph1arealworldstudy AT jingvoonchen treatmentpreferencesamongindividualswithprimaryhyperoxaluriatype1ph1arealworldstudy AT rebekahzincavage treatmentpreferencesamongindividualswithprimaryhyperoxaluriatype1ph1arealworldstudy AT bradpadilla treatmentpreferencesamongindividualswithprimaryhyperoxaluriatype1ph1arealworldstudy AT matthewsussman treatmentpreferencesamongindividualswithprimaryhyperoxaluriatype1ph1arealworldstudy AT sandrasalem treatmentpreferencesamongindividualswithprimaryhyperoxaluriatype1ph1arealworldstudy AT frankmodersitzki treatmentpreferencesamongindividualswithprimaryhyperoxaluriatype1ph1arealworldstudy |